SCRIBE THERAPEUTICS INC. Net Fee Amt
SCRIBE THERAPEUTICS INC. (SCTX) had Net Fee Amt of $6.79 thousand as of 2026-07-24, per its S-8 filed 2026-07-27.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-27
- 2026-07-24: Net Fee Amt $6.79K.
- 2026-07-23: Net Fee Amt $3.41K.
- 2026-07-20: Net Fee Amt $6.68K.
- 2026-07-02: Net Fee Amt $10.36K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-24 | $6.79K S-8 · filed 2026-07-27 |
| 2026-07-23 | $3.41K S-1MEF · filed 2026-07-23 |
| 2026-07-20 | $6.68K S-1/A · filed 2026-07-20 |
| 2026-07-02 | $10.36K S-1 · filed 2026-07-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |